Main Page Article Search E-Lerts™ Newsletter: Current E-Lerts™ Newsletter Archives E-Lerts™ Newsletter Recipes Archives Defeat Diabetes® E-Lerts™ Newsletter Subscribe Defeat Diabetes ® News by Daniel H. Rasolt Books You Can Use™ Subscribe to Defeat Diabetes Foundation Mailings
About Diabetes Body Care Children Complications Defeat Diabetes Foundation Drugs    » ACE Inhibitor    » Actos    » Alternative Medicine    » Aspirin    » Avandia    » Byetta    » Drugs    » Exenatide    » Glargine    » Glucophage    » Insulin    » Januvia    » Lantus    » Liraglutide    » Metformin    » Recall    » Research    » Rosiglitazone    » Self-Management    » Statins    » Sulfonylureas    » Victoza Elderly E-Lerts™ Governments & Organizations Health & Fitness Insulin MADDCAP™ Mr. Diabetes® Nutrition Obesity Other Diseases Pregnancy Research Risks Self-Management Supplements Type 1 Warning Signs

 

 

 

     

Drugs » Exenatide

Search our News Articles Archives for diabetes and health news. Search by word or phrase.  The latest article will appear first.

Search For:  

Search in all categories / subcategories
Search in current category / subcategory

Once-Weekly Exenatide Provides Glycemic Control and Weight Loss Posted: Wednesday, June 17, 2009

Once-weekly exenatide (EQW) produces superior improvements in glucose control and body weight compared with maximum daily doses of sitagliptin and pioglitazone on background metformin, according to study results presented at the ADA 69th Scientific Sessions.

Exenatide Not Associated with Increased Rate of Acute Pancreatitis Compared to other Antidiabetic Drugs Posted: Wednesday, June 17, 2009

Retrospective Cohort Study included more than 25,000 BYETTA patients accrued over three years.

Exenatide Improves Beta-Cell Function Compared with Insulin Glargine Posted: Wednesday, June 03, 2009

Over a 1-year period, treatment with exenatide improved beta-cell function significantly more, and led to greater weight loss, than did insulin glargine, in a study of patients with Type 2 diabetes who had previously been treated with metformin.

New Drug Might Replace Daily Insulin Injections Posted: Monday, September 08, 2008

For people with progressed type 2 diabetes that requires daily insulin injections, there might be a partial solution to this constant inconvenience. A new type 2 diabetes treatment has recently been developed that requires only one weekly treatment, and early results seem to indicate it is substantially effective.

No Efficacy or Safety Sacrifice with Weekly Exenatide (Byetta LAR) Posted: Friday, June 20, 2008

A long-acting version of the injectable diabetes drug exenatide (Byetta) showed efficacy advantages and safety comparable to the standard formulation given twice a day, researchers said.

Monotherapy BYETTA(R) (Exenatide) As Stand Alone Therapy Posted: Wednesday, June 11, 2008

Submitted to FDA for Stand-Alone Therapy in Q1 2008, studies show that exenatide can lower A1c 0.7 to 0.9 points as a monotherapy.

Type 2 Patients Taking Exenatide Once Weekly Improved Glycemic Control, Weight, and Lipid Profiles Posted: Wednesday, June 11, 2008

Amylin, Eli Lilly and Alkermes announced results from the DURATION-1 trial, a 30-week study that compared the efficacy of exenatide once weekly, a long-acting release formulation of exenatide, to BYETTA(R) (exenatide) injection.

 

 

 

 

 

 Costa Rica Travel Corp. will donate a portion of the proceeds to and is a sponsor of Defeat Diabetes Foundation.